Skip to main content

The Globe and Mail

Valeant profit plummets despite healthy revenue increase

Valeant Pharmaceuticals International Inc. CEO Michael Pearson is seen in one of the company's laboratories.


Valeant Pharmaceuticals International Inc. has seen a sharp drop in third-quarter profit despite a healthy increase in revenue.

Canada's largest publicly traded drug maker reported Friday that its net income for the three months ended Sept. 30 fell to just $7.6-million(U.S.) or 2 cents per diluted share.

That compared with net earnings of $40.9-million or 13 cents in the same 2011 period.

Story continues below advertisement

Revenue soared to $884.1-million from $570. 4 million.

On a cash EPS basis, adjusted income was $357.5-million, or $1.15 per diluted share. Analysts expected Valeant's adjust earnings to be $1.12 per share based on 17 estimates compiled by Thomson Reuters.

Revenue was estimated at $873.35-million, based on 15 estimates.

Valeant has made more than a dozen acquisitions this year to help strengthen its position as a global leader in dermatology products, including the recent purchase of U.S.-based Medicis Pharmaceutical Corp. for $2.6-billion.

Valeant also bought Dermik, a dermatological unit of Sanofi in the U.S. and Canada that manufactures, markets and sells a range of therapeutic and aesthetic dermatology products.

Last year, it bought Edmonton-based Afex Life Sciences, maker of the popular over-the-counter cold and flu remedy Cold-FX.

Another acquisition was iNova, which sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Southeast Asia and South Africa.

Story continues below advertisement

Valeant, formed from the combination of California-based Valeant and the former Biovail pharmaceutical company, announced in April that it would move its global headquarters to Quebec to focus on over-the-counter dermatology products. It's also setting up a research and development centre for consumer dermatology in Laval, north of Montreal.

Report an error Licensing Options

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Globe Newsletters

Get a summary of news of the day

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at